Recently, sotorasib and MRTX849 showed prolonged survival time and fewer adverse effects in patients with KRAS-driven NSCLC [9,10], indicating that TKI therapy targeting KRAS may become more critical, and, therefore, testing for KRAS mutant status before selecting a specific treatment may also become more critical. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.